

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8399343

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE		
CONVEYING PARTY DATA			
Name			Execution Date
FOX CHASE CANCER CENTER			02/16/2022
RECEIVING PARTY DATA			
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government		
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)		
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20892-7980		
PROPERTY NUMBERS Total: 1			
Property Type	Number		
Application Number:	14540428		
CORRESPONDENCE DATA			
Fax Number:	(301)480-0272		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	edison@nih.gov		
Correspondent Name:	DIRECTOR, DEITR		
Address Line 1:	NIH, 6705 ROCKLEDGE DRIVE, SUITE 310		
Address Line 2:	MSC 7980		
Address Line 4:	BETHESDA, MARYLAND 20892-7980		
NAME OF SUBMITTER:	DIRECTOR, DEITR		
SIGNATURE:	/DIRECTOR, DEITR/		
DATE SIGNED:	01/24/2024		
Total Attachments: 1			
source=14540428#page1.tif			

License to the United States Government

Sign and submit the executed document to the appropriate funding agency (e.g. upload in iEdison).

Invention Title: COMBINATION OF DNA REPAIR INHIBITION WITH BENDAMUSTINE OR GEMCITABINE IN THE TREATMENT OF CANCER

Inventor(s): Vikram Bhattacharjee, Pietro Mancuso, Neil Beeharrry, Alfonso Bellacosa, Mitchell Smith, Timothy J Yen, Rossella Tricarico

U.S. Filing/Issue Date: 11/13/2014

Patent or Application Serial No.: 14/540,428

Grant/Contract Number(s): CA078412, GMD66877, WRLXWS-11-1-0201

Foreign Applications filed/intended in (countries): _____


The invention identified above is a Subject Invention under **35 U.S.C. 200, et seq.** , and the Standard Patent Rights clause at **37 CFR 401.14, FAR 52.227-11 or FAR 52.227-12** (if applicable) which are included among the terms of the above identified grant or contract award from the United States Government. This document is confirmatory of:

1. The nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United States the invention described in any patent application and in any and all divisions, continuations, and continuations in part, and in any and all patents and re-issues granted thereon throughout the world; and
2. All other rights acquired by the Government by reason of the above identified grant/contract award and the laws and regulations that are applicable to the award.

The Government is hereby granted an irrevocable power to inspect and make copies of the above-identified patent application.

Signed this 16th day of February, 2022

By Kurt A. Schwinghammer, Ph.D.
(Institutional Business Official)


(Signature)

Title Vice President, R & D Alliances

For FOX CHASE CANCER CENTER
(Grantee/Contractor Organization)

At 333 Cottman Avenue Philadelphia, PA 19111
(Business Address)